Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Mar 15, 2024 4:37pm

198 Views

Post# 35935717

More great News today

with 1 Canadian site in Calgary and two more coming plus additional 3 sites in Turkey which will bring us to 9. It will be a big bonus if we get a few USA sites get us to 12-15 total sites.

Momentum iis definitely shifting, volume increasing daily and I feel the short squeeze has begun.

We closed at $2.20 today and are up 26% for the week which is awesome. We are only .18 cents away from 52 week high of $2.38 and would not be surprised we hit new 52 week high next week.

<< Previous

Bullboard Posts

Next >>

Fobi AI responds to cease trade order, filing delay “disappointing”